NCT04763317

Precision Medicine in the Prostate Cancer Care Pathway

Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of / Living With Prostate Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: Institute of Cancer Research, United Kingdom · Academic / Other
• Sex: Male
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.

Conditions

• Prostate Cancer
• Genetic Predisposition

Interventions

Type	Name	Description
GENETIC	Prostate cancer risk gene panel	A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy

Timeline

• Start date: 2019-02-14
• Primary completion: 2029-12-31
• Completion: 2034-12-01
• First posted: 2021-02-21
• Last updated: 2025-12-16

Locations

1 site across 1 country: United Kingdom